The protective role of HBV infection in glycolipid metabolism and related diseases, which are characterized by lower prevalence of NAFLD, hypertriglyceridemia, MetS [3, 6, 55], and IR rate [56], are likely to counteract the effect of PNPLA3 polymorphism. Here, PNPLA3 is linked to metabolic syndrome.